Program
icotrokinra
Also written as “JNJ-77242113”, “Icotrokinra” and “PN-235”.
Its studies are mostly in Psoriasis · Arthritis, Psoriatic · Colitis, Ulcerative · Crohn Disease, led by 2 companies.
Drug pageIcotrokinra: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnsonits history only | 137 open or running | phase 3since Oct 18, 2023 | Sep 21, 2021 | Feb 10, 2027phase 3 · NCT06807424 |
| Protagonist Therapeutics | 10 open or running | phase 1since Oct 29, 2020 | Oct 29, 2020 | none ahead |
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseJohnson & Johnson licensed it from Protagonist Therapeutics, for worldwide rights from phase 2 on.Agreed 2017 · Source: Johnson & Johnson, Mar 8, 2025
History and studies of Protagonist Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- 2017Johnson & Johnson licensed it from Protagonist TherapeuticsLicenseWorldwide rights from phase 2 on · agreed · Johnson & Johnson
- Oct 29, 2020First study: phase 1 study in Healthy VolunteersFirst studyNCT04621630 · 107 enrolled · Australia
- Feb 29, 2024Named icotrokinraINNProposed as its International Nonproprietary Name in WHO's List 130 · before, JNJ-77242113, PN-235
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Protagonist Therapeutics leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04621630Healthy Volunteers · Australia | 1 | Completed | Sep 19, 2021 | 107 |
How it is read
Names in the registry
- “JNJ-77242113”, 9 entries
- “Icotrokinra”, 4 entries
- “PN-235”, 1 entry
Codes read as this program: PN235.
Conditions, from the studies’ own filings
- Psoriasis, 6 studies
- Arthritis, Psoriatic, 2 studies
- Colitis, Ulcerative, 2 studies
- Crohn Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.